Report: Washington life sciences companies landed over $5B last year

Washington life science companies brought in about $5.1 billion in total investment last year, according to Life Science Washington’s first-annual 2021 Washington State Investor Report.

Over 180 investors participated in 112 life sciences deals ranging from venture capital, public offerings, mergers and acquisitions, and reverse mergers. Amgen’s purchase of Seattle-based Rodeo Therapeutics for$55 million with $666 million in potential milestone payments was the largest single deal in 2021, according to the report.

In all, mergers and acquisitions accounted for $1.8 billion of the total investment, followed by initial public offerings for $1.1 billion and early-stage venture capital for $889 million, while later-stage venture capital contributed $849 million.

READ THE STORY at Puget Sound Business Journal»